Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms | MicrobiomeTrials
Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2026-06-15Est. Completion: 2030-01-01
Enrollment target: 160 participants
Locations
National Institutes of Health Clinical Center, Bethesda, Maryland, United States